Methemoglobinemia and Tumor Lysis Syndrome
Methemoglobinemia and Tumor Lysis Syndrome is a research topic within Pulmonary and Respiratory Medicine. Science Explorer counts 7k research works in it since 1950. 14.2% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the management, treatment, and complications of tumor lysis syndrome (TLS), a potentially life-threatening oncologic emergency characterized by metabolic disturbances. The papers cover various aspects including therapeutic strategies, classification, prophylaxis, risk evaluation, and the use of medications such as rasburicase and dapsone. Additionally, the cluster discusses related conditions like methemoglobinemia and hyperuricemia, particularly in pediatric and adult patients undergoing chemotherapy for hematologic malignancies.
- Tumor Lysis Syndrome
- Rasburicase
- Methemoglobinemia
- Hyperuricemia
- Dapsone
- Chemotherapy
- Pediatric Oncology
- Acute Kidney Injury
- Oncologic Emergencies
- Urate Oxidase
- Research works
- 7k fractional, since 1950
- In the world top 10%
- 992 per year above
- Top-10% rate
- 14.2% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +27% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Methemoglobinemia and Tumor Lysis Syndrome research?
By volume, the United States and India publish the most (283 and 130 works in 2022–2025).
By volume, 2022–2025
- 1 United States 283 works
- 2 India 130 works
- 3 China 104 works
- 4 Japan 42 works
- 5 Türkiye 39 works
- 6 United Kingdom 31 works
- 7 Brazil 29 works
- 8 France 27 works
- 9 Iran 25 works
- 10 Italy 25 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Methemoglobinemia and Tumor Lysis Syndrome research?
By volume in 2022–2025, All India Institute of Medical Sciences publishes the most Methemoglobinemia and Tumor Lysis Syndrome research, followed by Post Graduate Institute of Medical Education and Research and Sağlık Bilimleri Üniversitesi.
By volume, 2022–2025
- 1 All India Institute of Medical SciencesIndia 5 works
- 2 Post Graduate Institute of Medical Education and ResearchIndia 5 works
- 3 Sağlık Bilimleri ÜniversitesiTürkiye 5 works
- 4 Tehran University of Medical SciencesIran 3 works
- 5 Hamad Medical CorporationQatar 3 works
- 6 Icahn School of Medicine at Mount SinaiUnited States 3 works
- 7 Cleveland ClinicUnited States 3 works
- 8 University of California, San FranciscoUnited States 3 works
- 9 The University of Texas MD Anderson Cancer CenterUnited States 3 works
- 10 Massachusetts General HospitalUnited States 3 works
Where is Methemoglobinemia and Tumor Lysis Syndrome research done?
The largest centres of Methemoglobinemia and Tumor Lysis Syndrome research in 2022–2025 are New York (United States), New Delhi (India), Istanbul (Türkiye) and Tokyo (Japan).
Largest cities, 2022–2025
Is Methemoglobinemia and Tumor Lysis Syndrome research growing?
Output in 2018–2022 was 27% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Methemoglobinemia and Tumor Lysis Syndrome.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.